BMI View: Israel’s pharmaceutical market is a very attractive prospect for multinationals looking to launch innovative medicines. Favourable factors include high per capita spending on medicines, a market size approaching US$2bn, a high proportion of pensioners and a largely urbanised population. However, we caution that poor patent respect and a lack of business transparency remain key threats to company revenues. Additionally, we hold a relatively less optimistic outlook for growth in the market, based on weaker private consumption over the medium term. Headline Expenditure Projections ? Pharmaceuticals: ILS7.13bn (US$1.85bn) in 2012 to ILS7.39bn (US$2.05bn) in 2013; +3.7% in local currency …
Order / Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=117445.
Complete report details with Table of Contents and more @ http://www.rnrmarketresearch.com/israel-pharmaceuticals-and-healthcare-report-q4-2013-market-report.html.
No comments:
Post a Comment